Key Segments
By Product
-
Naltrexone
-
Buprenorphine
-
BELBUCA
-
Sublocade
-
Suboxone
-
Zubsolv
-
Others
-
By Route of Administration
-
Naltrexone
-
Oral Administration
-
Injectable Administration
-
Implantable Administration
-
-
Buprenorphine
-
Oral Administration
-
Injectable Administration
-
Implantable Administration
-
By Application
-
Naltrexone
-
Opioid use disorder (OUD)
-
Alcohol use disorder (AUD)
-
-
Buprenorphine
-
Opioid use disorder (OUD)
-
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
-
Mexico
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Turkey
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Singapore
-
Australia
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g., Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Ans: North America dominated the Naltrexone and Buprenorphine market.
Ans: One significant barrier is MAT (medication-assisted treatment) related stigma, which restricts reach, even among individuals who have been diagnosed.
Ans: Growing access to naltrexone and buprenorphine globally, heightened government support, and advancements in drug delivery devices are factors driving the naltrexone and buprenorphine market.
Ans: The market is expected to reach USD 8.54 billion by 2032, increasing from USD 4.20 billion in 2024.
Ans: The Naltrexone and Buprenorphine market is anticipated to grow at a CAGR of 9.30% from 2025 to 2032.